| P2093 | author name string | Dwarakanathan Ranganathan | |
| | Tien K Khoo | |
| | Alfred K Lam | |
| | Zaw Thet | |
| | Soe Yu Aung | |
| P2860 | cites work | Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair | Q26822549 |
| | 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides | Q28276589 |
| | Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. | Q30696868 |
| | Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence | Q33346685 |
| | Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials | Q33913430 |
| | CKD and the risk of incident cancer | Q34259993 |
| | Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis | Q34375512 |
| | Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort | Q34628409 |
| | Rituximab versus cyclophosphamide for ANCA-associated vasculitis | Q35109118 |
| | Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide | Q35553364 |
| | Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies | Q35606909 |
| | Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years | Q37001231 |
| | Association of CKD and cancer risk in older people | Q37211112 |
| | Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis | Q37682245 |
| | Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. | Q37686029 |
| | ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships | Q38090841 |
| | Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis | Q38404163 |
| | The immune status of the uremic patient: hemodialysis vs CAPD. | Q39533653 |
| | Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate | Q41022599 |
| | Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis | Q41676109 |
| | Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 |
| | Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients | Q44070249 |
| | Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients | Q44698206 |
| | Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis | Q44772811 |
| | Wegener Granulomatosis: An Analysis of 158 Patients | Q45267316 |
| | Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study | Q45399316 |
| | Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. | Q46006712 |
| | Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. | Q46117432 |
| | Azathioprine or methotrexate maintenance for ANCA-associated vasculitis | Q46182931 |
| | Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis. | Q47794092 |
| | Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study. | Q48102349 |
| | Quantification of cancer risk in glomerulonephritis. | Q48113533 |
| | AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives | Q50061906 |
| | Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. | Q50621689 |
| | DNA repair and recovery of RNA synthesis in uremic patients | Q53479197 |
| | Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. | Q55055285 |
| | Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis | Q73036641 |
| | Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis | Q74456170 |
| | Glomerulonephritis associated with basaloid squamous cell carcinoma of the oesophagus. A possible unusual paraneoplastic syndrome | Q74484594 |
| | Cancer in end-stage renal disease: potential factors involved -editorial- | Q74504880 |
| | Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement | Q74575389 |
| | Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre | Q84599916 |
| | Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades | Q85070315 |
| P577 | publication date | 2020-03-26 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis | |